Please provide your email address to receive an email when new articles are posted on . This is the first biologics license application submitted for a gene-agnostic retinal disease gene therapy.

Rocket Pharmaceuticals has withdrawn its application seeking Food and Drug Administration approval of its RP-L102 proposed gene therapy for the treatment of the rare, inherited blood disorder Fanconi ...

Rocket Pharmaceuticals (NASDAQ:RCKT) reported that it has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogene autotemcel or RP-L102, an investigational gene ...